• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer

    2/23/22 9:00:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNA alert in real time by email

    SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies.

    Steve Hughes

    "Steve brings a unique combination of extensive experience in the RNA field as well as a deep understanding of rare disease drug development," said Sarah Boyce, president and chief executive officer. "Steve's unparalleled leadership in developing RNA-based treatments across therapeutic areas will be invaluable as we expand our AOC platform and execute on our goal of having three programs in the clinic by the end of this year."

    Dr. Hughes has contributed to over 50 clinical trials for more than 25 drugs across multiple therapeutic areas including cardiovascular, neurology and several rare diseases. He has been closely involved in multiple registrational regulatory filings, including playing a key role in the approval of three rare disease products in the last six years.

    "I'm thrilled to be joining the talented team at Avidity. The AOC platform is a ground-breaking technology that significantly broadens the potential for RNA therapies," said Steve Hughes, M.D., chief medical officer at Avidity. "I look forward to contributing to Avidity's progress in the clinic during this pivotal time as we work to advance our clinical programs and deliver potentially transformative medicines to people living with rare diseases that have limited or no therapeutic options."

    Dr. Hughes joins Avidity from Arcturus Therapeutics where he continues to be a strategic clinical advisor. Prior to that, he held the position of CMO where he provided leadership and direction to clinical operations, clinical development, clinical sciences, data management, biometrics, and drug safety. Prior to Arcturus, he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for the treatment of hepatic and renal diseases. Dr. Hughes's previous positions include the Chief Clinical Development Officer at Ionis Pharmaceuticals and positions at Biogen, CSL Behring and Sanofi. Dr. Hughes is board certified in pharmaceutical medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.

    About Avidity Biosciences

    Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity is on track to have three programs in clinical development by the end of 2022. The company's lead product candidate, AOC 1001, is designed to treat patients with myotonic dystrophy type 1 (DM1). AOC 1001 has commenced clinical testing with the ongoing Phase 1/2 MARINA™ trial in adults with DM1. The next programs in the company's advancing and expanding pipeline are AOC 1044, the lead of three programs for the treatment of DMD, and AOC 1020, designed to treat people living with FSHD. Avidity anticipates both programs will enter the clinic by the end of 2022.  Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

    Forward-Looking Statements

    Avidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements and cautions readers not to place undue reliance on these forward-looking statements. These statements are based on the company's current beliefs and expectations, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. Such forward-looking statements include, but are not limited to, statements regarding: the potential to develop a meaningful pipeline of novel AOC therapeutics; the progression of clinical programs for AOC 1001, AOC 1044 and AOC 1020 and timing of ongoing and planned clinical trials; and the broad potential of AOCs to treat rare and serious diseases. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the business, including, without limitation: Avidity is early in its development efforts; Avidity's approach to the discovery and development of product candidates based on its AOC platform is unproven, and the company does not know whether it will be able to develop any products of commercial value; potential delays in the commencement, enrollment and completion of clinical trials;  the success of its preclinical studies and clinical trials for the company's product candidates; the results of preclinical studies and early clinical trials are not necessarily predictive of future results;  unexpected adverse side effects or inadequate efficacy of its product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; and other risks described in prior press releases and in filings with the Securities and Exchange Commission (SEC). All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Contacts:

    Kathleen Gallagher

    (858) 401-7900

    [email protected]

    Media Contact:

    Cherise Adkins

    [email protected]

    (301) 267-4161

    (PRNewsfoto/Avidity Biosciences, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-appoints-steve-hughes-md-as-chief-medical-officer-301488014.html

    SOURCE Avidity Biosciences, Inc.

    Get the next $RNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNA

    DatePrice TargetRatingAnalyst
    9/17/2025$62.00Buy
    Roth Capital
    7/10/2025$55.00Buy
    Goldman
    6/24/2025$50.00Outperform
    Bernstein
    6/17/2025$55.00Outperform
    Wolfe Research
    6/11/2025$65.00Strong Buy
    Raymond James
    3/13/2025$70.00Buy
    Citigroup
    3/12/2025$72.00Outperform
    BMO Capital Markets
    3/7/2025$70.00Sector Outperform
    Scotiabank
    More analyst ratings

    $RNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $40.00 per share. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $690.0 million. All of the shares sold

    9/15/25 4:01:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

    SAN DIEGO, Sept. 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600.0 million. The offering is expected to close on or about September 15, 2025, subject to t

    9/11/25 7:56:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avidity Biosciences Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of common stock. All of the shares to be sold in the offering are to be sold by Avidity. There can be no assurance as to whether or when the offering may be completed, or as to the ac

    9/10/25 4:01:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Hughes Steven George exercised 2,208 shares at a strike of $10.16 and sold $89,601 worth of shares (2,208 units at $40.58) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/23/25 4:57:37 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Human Resources Officer Mccarthy Teresa exercised 15,000 shares at a strike of $22.34 and sold $621,142 worth of shares (15,000 units at $41.41) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/17/25 4:03:37 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Hughes Steven George exercised 1,542 shares at a strike of $6.57 and sold $70,022 worth of shares (1,542 units at $45.41) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/17/25 4:02:14 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    SEC Filings

    View All

    SEC Form 8-K filed by Avidity Biosciences Inc.

    8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

    9/12/25 5:23:24 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Avidity Biosciences Inc.

    424B5 - Avidity Biosciences, Inc. (0001599901) (Filer)

    9/12/25 4:53:54 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Avidity Biosciences Inc.

    424B5 - Avidity Biosciences, Inc. (0001599901) (Filer)

    9/10/25 4:59:56 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Avidity Biosciences with a new price target

    Roth Capital initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $62.00

    9/17/25 7:57:56 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Avidity Biosciences with a new price target

    Goldman resumed coverage of Avidity Biosciences with a rating of Buy and set a new price target of $55.00

    7/10/25 8:52:40 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Avidity Biosciences with a new price target

    Bernstein initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $50.00

    6/24/25 7:59:27 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Financials

    Live finance-specific insights

    View All

    Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting

    Discussions with the FDA ongoing as Avidity submits emerging AOC 1001 data from the MARINA trial AOC 1001 continues to be generally well tolerated; Avidity provides more information on the rare serious adverse event in a single participant that led to the partial clinical hold AOC 1001 top-line safety and functional data to be presented at the American Academy of Neurology (AAN) Annual Meeting on April 27, 2023 Avidity to hold a webcast/conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, March 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates

    3/30/23 7:07:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

    Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of A

    9/27/22 7:00:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 1:22:38 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avidity Biosciences Inc.

    SC 13G - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 9:39:22 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNA
    Leadership Updates

    Live Leadership Updates

    View All

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer

    SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of John B. Moriarty, Jr., J.D., as Chief Legal Officer and Corporate Secretary, effective immediately. With almost 30 years of industry experience, Mr. Moriarty brings extensive legal expertise and a proven track record of successfully guiding leading global biotech companies through transformational growth. Mr. Moriarty succeeds Joh

    8/5/24 9:00:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products